Indication
NFE2L2 Gene Mutation
2 clinical trials
7 products
Clinical trial
A Randomized, Open-Label Phase 2 Study of the TORC 1/2 Inhibitor Sapanisertib in Relapsed/Refractory NFE2L2 (NRF2)-Mutated and Wild-Type (WT) Squamous Non-Small Cell Lung Cancer (sqNSCLC)Status: Terminated, Estimated PCD: 2023-03-10
Product
sapanisertibProduct
TelaglenastatClinical trial
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)Status: Terminated, Estimated PCD: 2021-11-05
Product
DexamethasoneProduct
CarboplatinProduct
PemetrexedProduct
PembrolizumabProduct
Placebo